Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles

Documenti analoghi

• Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
  di: Attili, Ilaria, et al.
  Pubblicazione: (2020)
• Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?
  di: Cheng, Michael L., et al.
  Pubblicazione: (2018)
• The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
  di: Lin, Chutong, et al.
  Pubblicazione: (2021)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  di: Wen, Miaomiao, et al.
  Pubblicazione: (2018)
• Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
  di: Wei, Zhigang, et al.
  Pubblicazione: (2017)